Fazili Afsaneh, Gholami Soghra, Sheikhpour Mojgan, Pousti Pegah
Department of Anatomy, School of Veterinary Medicine, Shiraz University, P.O.Box: 14115-111, Fars, Iran.
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
J Diabetes Metab Disord. 2020 May 11;19(1):453-460. doi: 10.1007/s40200-020-00530-3. eCollection 2020 Jun.
The main goal of diabetes therapy is to control blood glucose levels.
In this study, the effect of Matricaria chamomilla L. oil as an herbal agent, on therapeutic properties of poly L-lactic acid-based (PLLA) scaffold loaded with differentiated stem cells, is examined in the diabetic rabbit.
Adipose mesenchymal stem cells (AMSCs) were isolated from male New Zealand White rabbits and after seeding on the PLLA scaffold differentiated in the pancreatic region. In vivo differentiation of AMSCs toward pancreatic progenitor cells was evaluated by quantitative analysis of gene expressions and immunohistochemistry. Then, one normal and five diabetic groups including blank diabetic, scaffold, oil + scaffold, and differentiated cell + scaffold or oil + scaffold were assessed after 21 days of treatment. After the assessment, the diabetic groups were evaluated by clinical parameters and pancreatic histological sections.
It was found that AMSCs were differentiated to insulin-producing cells (IPCs) in the pancreatic environment which then used for implantation. Blood glucose in the oil + scaffold, cell + scaffold, and oil + cell + scaffold groups showed a significant decrease after 21 days. In the above mentioned three groups, insulin secretion was increased significantly. Chamomile oil also caused a significant decrease in High-density lipoprotein (HDL), Low-density lipoprotein (LDL), and total cholesterol levels. According to histological sections results, in cell + scaffold and oil + cell + scaffold groups, β cells were significantly increased compared to blank diabetic group.
Together these data demonstrated chamomile oil along with in vivo-differentiated stem cell is a promising new treatment for diabetes.
糖尿病治疗的主要目标是控制血糖水平。
在本研究中，考察了洋甘菊油作为一种草药制剂，对负载分化干细胞的聚左旋乳酸（PLLA）支架在糖尿病兔体内治疗特性的影响。
从雄性新西兰白兔中分离脂肪间充质干细胞（AMSCs），接种到PLLA支架上后在胰腺区域进行分化。通过基因表达定量分析和免疫组织化学评估AMSCs向胰腺祖细胞的体内分化情况。然后，在治疗21天后，评估1个正常组和5个糖尿病组，包括空白糖尿病组、支架组、油+支架组、分化细胞+支架组或油+支架组。评估后，通过临床参数和胰腺组织切片对糖尿病组进行评价。
发现AMSCs在胰腺环境中分化为胰岛素分泌细胞（IPCs），然后用于植入。油+支架组、细胞+支架组和油+细胞+支架组的血糖在21天后显著降低。在上述三组中，胰岛素分泌显著增加。洋甘菊油还导致高密度脂蛋白（HDL）、低密度脂蛋白（LDL）和总胆固醇水平显著降低。根据组织切片结果，与空白糖尿病组相比，细胞+支架组和油+细胞+支架组的β细胞显著增加。
这些数据共同表明，洋甘菊油与体内分化的干细胞一起是一种有前景的糖尿病新疗法。
